GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma. Twelve heavily pretreated patients received four intravenous infusio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Leo Rasche, Johannes Duell, Inês C. Castro, Valentina Dubljevic, Manik Chatterjee, Stefan Knop, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Max S. Topp, Stephanie Brändlein
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2015-03-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/7310
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!